StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note published on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock. Cellectis Price Performance Shares of NASDAQ CLLS traded up $0.36 during mid-day trading on Friday, reaching $3.35. 272,116 shares of the company traded hands, compared […]
StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research report report published on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock. Cellectis Stock Up 0.6 % Shares of CLLS opened at $2.51 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio […]
StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note released on Saturday morning. The brokerage issued a sell rating on the biotechnology company’s stock. Cellectis Price Performance NASDAQ:CLLS opened at $2.51 on Friday. The company’s 50-day moving average price is $2.62 and its 200-day moving average price is $2.65. […]
Shares of Cellectis S.A. (NASDAQ:CLLS – Get Free Report) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.71 and traded as high as $2.82. Cellectis shares last traded at $2.75, with a volume of 20,196 shares trading hands. Cellectis Stock Up 0.4 […]
By Ben Otto British drugmaker AstraZeneca plans to invest $245 million in a deal with biotechnology company Cellectis to develop next-generation therapeutics.